



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

June 2021





© 2021 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2021 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

June 2021

N = 7451



Health Authority	Male	Female	All
FRASER	1466	452	1918
INTERIOR	436	105	541
NORTHERN	131	79	210
VANCOUVER COASTAL	3364	445	3809
VANCOUVER ISLAND	776	169	945
	6173	1250	7423
		Unknown/not stated:	28
		Total:	7451

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown





1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (June 2016 - June 2021)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (June 2016 - June 2021)



Notes: Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month




1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (June 2016 - June 2021)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (June 2016 - June 2021)






1.6 Percent Distribution of Active Participants by CD4 Count (June 2016 - June 2021)






1.7 Percent Distribution of Inactive Participants by CD4 Count (June 2016 - June 2021)






1.8 Active and Inactive Participants (June 2016 - June 2021)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (June 2016 - June 2021)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (June 2016 - June 2021)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(June 2016 - June 2021)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (June 2016 - June 2021)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(June 2016 - June 2021)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (June 2016 - June 2021)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(June 2016 - June 2021)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (June 2016 - June 2021)





**1.17 Distribution of Participants on Entry/Integrase Inhibitors
at the time of first ARV Therapy by INGREDIENT
(June 2016 - June 2021)**






1.18 Baseline CD4 for Antiretroviral First Starts (June 2016 - June 2021)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (June 2016 - June 2021)






1.20 Cumulative Resistance Testing Results by Resistance Category (June 2016 - June 2021)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (June 2016 - June 2021)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2021
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	29	4	0	4	1	920	4	<40	4
1988	30	5	0	5	2	565	5	<40	3
1989	28	53	1	54	25	480	52	<40	3
1990	27	54	1	55	31	570	54	<40	3
1991	27	37	3	40	22	555	39	<40	3
1992	27	59	5	64	33	530	61	<40	3
1993	26	125	14	139	89	530	135	<40	3
1994	24	74	13	87	55	580	82	<40	3
1995	24	127	17	144	99	560	137	<40	3
1996	22	317	46	363	220	590	336	<40	3
1997	21	261	34	295	201	610	274	<40	3
1998	20	191	41	232	153	590	217	<40	3
1999	20	160	40	200	137	560	185	<40	3
2000	20	120	32	152	103	630	138	<40	3
2001	19	117	28	145	99	590	133	<40	3
2002	18	124	25	149	105	570	142	<40	3
2003	18	141	28	169	111	630	157	<40	3
2004	17	151	39	190	123	590	170	<40	3
2005	16	184	43	227	152	630	208	<40	3
2006	15	170	38	208	145	630	188	<40	3
2007	14	232	48	280	185	620	254	<40	3
2008	13	281	65	346	243	650	314	<40	3
2009	12	303	63	366	238	625	339	<40	3
2010	11	261	69	330	232	680	296	<40	3
2011	10	323	73	396	251	660	342	<40	3
2012	9	277	66	343	226	721	308	<40	3
2013	8	257	65	322	216	710	289	<40	3
2014	7	272	54	326	184	697	284	<40	3
2015	6	278	45	323	224	730	300	<40	3
2016	5	262	55	317	198	670	267	<40	3
2017	4	216	34	250	178	670	237	<40	3
2018	3	194	55	249	165	700	230	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2021
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
2019	2	234	40	274	198	645	251	<40	3
2020	1	192	53	245	186	655	232	<40	3
2021	0	130	22	152	134	517	146	<40	3
Total:		6186	1255	7441					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2020	7358	774	2227	<40	1728	610
FEB-2020	7329	776	1882	<40	1417	620
MAR-2020	7387	768	1628	<40	1207	620
APR-2020	7408	770	767	<40	577	600
MAY-2020	7397	776	1186	<40	892	600
JUN-2020	7368	784	1558	<40	1147	620
JUL-2020	7333	794	1918	<40	1437	610
AUG-2020	7254	791	1848	<40	1331	630
SEP-2020	7233	784	1735	<40	1239	620
OCT-2020	7266	776	1782	<40	1306	630
NOV-2020	7341	763	1858	<40	1282	610
DEC-2020	7349	752	1542	<40	1082	630
JAN-2021	7386	746	1942	<40	1374	630
FEB-2021	7376	748	1786	<40	1242	630
MAR-2021	7432	743	2017	<40	1380	628
APR-2021	7420	746	1828	<40	1254	640
MAY-2021	7452	746	1868	<40	1193	630
JUN-2021	7451	743	1877	<40	1189	620

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2020	635	185	70	354	46	435
FEB-2020	675	173	71	<40	58	480
MAR-2020	632	188	50	<40	32	415
APR-2020	611	204	28	116	22	555
MAY-2020	630	187	42	<50	30	490
JUN-2020	662	181	56	<40	46	480
JUL-2020	729	161	72	<40	56	625
AUG-2020	820	142	75	<40	65	470
SEP-2020	872	137	93	<40	71	610
OCT-2020	866	178	87	<40	75	570
NOV-2020	794	192	78	<40	62	510
DEC-2020	797	187	65	<40	54	430
JAN-2021	781	204	73	<40	55	510
FEB-2021	797	199	70	<40	56	510
MAR-2021	781	252	88	<40	70	630
APR-2021	811	260	73	<40	56	615
MAY-2021	794	276	73	<40	63	520
JUN-2021	798	264	68	<50	46	575

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2020	7328	635	10	12	183	155	18	13903
FEB-2020	7295	675	12	19	141	172	-33	13939
MAR-2020	7358	632	14	23	210	152	63	13975
APR-2020	7382	611	12	8	158	127	24	14000
MAY-2020	7375	630	10	15	130	135	-7	14025
JUN-2020	7346	662	8	9	125	149	-29	14042
JUL-2020	7309	729	15	12	160	189	-37	14074
AUG-2020	7222	820	18	11	168	241	-87	14094
SEP-2020	7193	872	19	9	228	241	-29	14115
OCT-2020	7227	866	20	13	223	175	34	14136
NOV-2020	7311	794	12	12	244	155	84	14162
DEC-2020	7327	797	10	13	205	189	16	14191
JAN-2021	7365	781	14	10	203	159	38	14211
FEB-2021	7355	797	15	14	184	192	-10	14235
MAR-2021	7411	781	15	24	203	155	56	14272
APR-2021	7401	811	13	9	166	170	-10	14297
MAY-2021	7427	794	14	15	176	147	26	14326
JUN-2021	7441	798	6	15	182	176	14	14352

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2020	60	6758	484	56	7358	0.82%	91.85%	6.58%	0.76%	100.00%
FEB-2020	59	6735	477	58	7329	0.81%	91.90%	6.51%	0.79%	100.00%
MAR-2020	60	6790	487	50	7387	0.81%	91.92%	6.59%	0.68%	100.00%
APR-2020	61	6814	483	50	7408	0.82%	91.98%	6.52%	0.67%	100.00%
MAY-2020	60	6806	481	50	7397	0.81%	92.01%	6.50%	0.68%	100.00%
JUN-2020	59	6774	484	51	7368	0.80%	91.94%	6.57%	0.69%	100.00%
JUL-2020	61	6753	471	48	7333	0.83%	92.09%	6.42%	0.65%	100.00%
AUG-2020	70	6676	457	51	7254	0.96%	92.03%	6.30%	0.70%	100.00%
SEP-2020	85	6640	456	52	7233	1.18%	91.80%	6.30%	0.72%	100.00%
OCT-2020	107	6646	462	51	7266	1.47%	91.47%	6.36%	0.70%	100.00%
NOV-2020	162	6674	456	49	7341	2.21%	90.91%	6.21%	0.67%	100.00%
DEC-2020	180	6659	461	49	7349	2.45%	90.61%	6.27%	0.67%	100.00%
JAN-2021	205	6683	452	46	7386	2.78%	90.48%	6.12%	0.62%	100.00%
FEB-2021	226	6651	448	51	7376	3.06%	90.17%	6.07%	0.69%	100.00%
MAR-2021	249	6669	463	51	7432	3.35%	89.73%	6.23%	0.69%	100.00%
APR-2021	275	6647	454	44	7420	3.71%	89.58%	6.12%	0.59%	100.00%
MAY-2021	299	6640	465	48	7452	4.01%	89.10%	6.24%	0.64%	100.00%
JUN-2021	326	6606	472	47	7451	4.38%	88.66%	6.33%	0.63%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		tenofovir <TAF>		tenofovir <TDF>		emtricitabine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2020	2 8%	3402 47%	2 8%	3226 45%	0 0%	34 0%	0 0%	1 0%	9 38%	1024 14%	13 54%	2963 41%	22 92%	3763 52%
FEB-2020	3 8%	3351 47%	3 8%	3179 45%	0 0%	33 0%	0 0%	1 0%	16 44%	1169 16%	17 47%	2825 40%	33 92%	3781 53%
MAR-2020	5 14%	3325 46%	5 14%	3160 44%	1 3%	34 0%	0 0%	1 0%	20 56%	1326 18%	11 31%	2719 38%	30 83%	3855 54%
APR-2020	6 24%	3298 46%	5 20%	3137 43%	1 4%	35 0%	0 0%	0 0%	8 32%	1402 19%	11 44%	2637 37%	19 76%	3888 54%
MAY-2020	1 4%	3272 45%	0 0%	3111 43%	0 0%	36 0%	0 0%	0 0%	13 54%	1481 21%	11 46%	2595 36%	23 96%	3914 54%
JUN-2020	5 29%	3242 45%	5 29%	3080 43%	0 0%	33 0%	0 0%	0 0%	4 24%	1585 22%	8 47%	2517 35%	12 71%	3921 55%
JUL-2020	6 19%	3199 45%	4 13%	3039 42%	2 6%	32 0%	0 0%	0 0%	14 44%	1695 24%	12 38%	2420 34%	26 81%	3942 55%
AUG-2020	3 15%	3149 45%	2 10%	2990 42%	0 0%	31 0%	0 0%	0 0%	11 55%	1759 25%	6 30%	2313 33%	17 85%	3913 55%
SEP-2020	3 14%	3121 44%	2 10%	2960 42%	0 0%	31 0%	0 0%	0 0%	13 62%	1868 26%	5 24%	2224 32%	18 86%	3927 56%
OCT-2020	2 10%	3122 44%	2 10%	2945 42%	0 0%	29 0%	0 0%	0 0%	12 57%	1971 28%	7 33%	2135 30%	19 90%	3961 56%
NOV-2020	7 27%	3165 44%	3 12%	2935 41%	1 4%	30 0%	0 0%	0 0%	11 42%	2063 29%	8 31%	2077 29%	19 73%	3990 56%
DEC-2020	3 10%	3152 44%	3 10%	2896 40%	0 0%	29 0%	0 0%	0 0%	14 48%	2145 30%	12 41%	2020 28%	26 90%	4012 56%
JAN-2021	2 10%	3154 44%	1 5%	2881 40%	0 0%	28 0%	0 0%	0 0%	12 60%	2221 31%	6 30%	1962 27%	18 90%	4046 56%
FEB-2021	2 8%	3134 43%	2 8%	2842 39%	0 0%	27 0%	0 0%	0 0%	16 67%	2298 32%	6 25%	1899 26%	22 92%	4061 56%
MAR-2021	8 22%	3139 43%	7 19%	2831 39%	0 0%	24 0%	0 0%	0 0%	23 62%	2368 33%	6 16%	1859 26%	29 78%	4112 57%
APR-2021	2 8%	3139 43%	2 8%	2804 39%	0 0%	25 0%	0 0%	0 0%	17 68%	2422 33%	6 24%	1792 25%	23 92%	4105 57%
MAY-2021	7 24%	3148 43%	3 10%	2782 38%	0 0%	22 0%	0 0%	0 0%	15 52%	2499 34%	10 34%	1759 24%	22 76%	4133 57%
JUN-2021	4 15%	3133 43%	3 12%	2737 38%	0 0%	23 0%	0 0%	0 0%	17 65%	2575 35%	5 19%	1697 23%	22 85%	4152 57%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	fosamprenavir		atazanavir		darunavir		lopinavir		ritonavir		saquinavir		tipranavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2020	0 0%	2 0%	0 0%	910 37%	6 86%	1466 59%	1 14%	96 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
FEB-2020	0 0%	2 0%	1 11%	873 36%	8 89%	1454 60%	0 0%	96 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
MAR-2020	0 0%	2 0%	1 10%	860 36%	9 90%	1434 60%	0 0%	93 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
APR-2020	0 0%	2 0%	0 0%	838 36%	4 80%	1412 60%	1 20%	93 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
MAY-2020	0 0%	2 0%	1 10%	834 36%	9 90%	1411 60%	0 0%	89 4%	0 0%	0 0%	0 0%	6 0%	0 0%	0 0%
JUN-2020	0 0%	2 0%	2 33%	812 35%	4 67%	1386 61%	0 0%	86 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
JUL-2020	0 0%	1 0%	0 0%	779 35%	8 100%	1359 61%	0 0%	81 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
AUG-2020	0 0%	1 0%	1 20%	749 35%	4 80%	1327 62%	0 0%	79 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
SEP-2020	0 0%	0 0%	1 33%	734 35%	2 67%	1298 61%	0 0%	79 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
OCT-2020	0 0%	0 0%	0 0%	711 34%	6 100%	1281 62%	0 0%	77 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
NOV-2020	0 0%	1 0%	0 0%	694 34%	3 100%	1270 62%	0 0%	77 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
DEC-2020	0 0%	1 0%	1 8%	677 33%	11 92%	1286 63%	0 0%	76 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
JAN-2021	0 0%	1 0%	0 0%	655 32%	5 100%	1297 64%	0 0%	71 4%	0 0%	1 0%	0 0%	6 0%	0 0%	1 0%
FEB-2021	0 0%	1 0%	0 0%	643 33%	5 100%	1262 64%	0 0%	71 4%	0 0%	1 0%	0 0%	5 0%	0 0%	1 0%
MAR-2021	0 0%	1 0%	1 25%	621 32%	3 75%	1261 65%	0 0%	73 4%	0 0%	1 0%	0 0%	5 0%	0 0%	1 0%
APR-2021	0 0%	1 0%	0 0%	595 31%	4 100%	1231 65%	0 0%	72 4%	0 0%	1 0%	0 0%	2 0%	0 0%	1 0%
MAY-2021	0 0%	1 0%	0 0%	589 31%	4 100%	1239 65%	0 0%	69 4%	0 0%	1 0%	0 0%	1 0%	0 0%	1 0%
JUN-2021	0 0%	1 0%	0 0%	572 31%	4 80%	1222 66%	1 20%	69 4%	0 0%	1 0%	0 0%	1 0%	0 0%	1 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2020	0 0%	1 0%	3 100%	590 36%	0 0%	202 12%	0 0%	501 31%	0 0%	325 20%
FEB-2020	0 0%	1 0%	4 100%	558 36%	0 0%	198 13%	0 0%	483 31%	0 0%	320 21%
MAR-2020	0 0%	1 0%	4 100%	547 36%	0 0%	195 13%	0 0%	464 31%	0 0%	315 21%
APR-2020	0 0%	1 0%	6 86%	542 36%	0 0%	190 13%	0 0%	456 30%	1 14%	313 21%
MAY-2020	0 0%	1 0%	1 50%	536 36%	0 0%	193 13%	0 0%	452 30%	1 50%	305 21%
JUN-2020	0 0%	1 0%	2 100%	524 36%	0 0%	189 13%	0 0%	447 30%	0 0%	307 21%
JUL-2020	0 0%	3 0%	2 50%	507 35%	0 0%	184 13%	2 50%	438 31%	0 0%	305 21%
AUG-2020	1 100%	4 0%	0 0%	501 36%	0 0%	179 13%	0 0%	421 30%	0 0%	294 21%
SEP-2020	0 0%	5 0%	1 33%	476 35%	0 0%	174 13%	0 0%	409 30%	2 67%	293 22%
OCT-2020	0 0%	9 1%	1 100%	461 35%	0 0%	171 13%	0 0%	402 30%	0 0%	279 21%
NOV-2020	0 0%	10 1%	2 67%	451 35%	0 0%	171 13%	1 33%	393 30%	0 0%	279 21%
DEC-2020	0 0%	11 1%	2 67%	437 34%	0 0%	163 13%	0 0%	383 30%	1 33%	276 22%
JAN-2021	0 0%	11 1%	1 100%	426 34%	0 0%	164 13%	0 0%	379 30%	0 0%	272 22%
FEB-2021	0 0%	15 1%	0 0%	418 34%	0 0%	161 13%	0 0%	365 30%	0 0%	267 22%
MAR-2021	0 0%	21 2%	2 100%	419 34%	0 0%	162 13%	0 0%	365 30%	0 0%	266 22%
APR-2021	0 0%	20 2%	1 50%	409 34%	0 0%	155 13%	1 50%	359 30%	0 0%	260 22%
MAY-2021	1 20%	30 3%	3 60%	397 33%	0 0%	154 13%	0 0%	353 30%	1 20%	259 22%
JUN-2021	0 0%	41 4%	2 100%	379 32%	0 0%	155 13%	0 0%	345 30%	0 0%	252 22%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2020	9 50%	421 10%	7 39%	2687 62%	0 0%	707 16%	0 0%	32 1%	2 11%	594 14%
FEB-2020	14 52%	602 14%	11 41%	2642 60%	2 7%	654 15%	0 0%	29 1%	0 0%	576 13%
MAR-2020	19 68%	755 17%	7 25%	2623 58%	1 4%	623 14%	1 4%	30 1%	0 0%	562 12%
APR-2020	7 50%	827 18%	6 43%	2589 57%	1 7%	607 13%	0 0%	29 1%	0 0%	544 12%
MAY-2020	10 56%	911 20%	6 33%	2554 56%	2 11%	597 13%	0 0%	27 1%	0 0%	541 12%
JUN-2020	4 31%	1022 22%	9 69%	2537 55%	0 0%	582 13%	1 8%	28 1%	0 0%	538 12%
JUL-2020	9 38%	1140 24%	10 42%	2508 54%	5 21%	549 12%	0 0%	29 1%	0 0%	527 11%
AUG-2020	10 59%	1219 26%	6 35%	2458 52%	1 6%	517 11%	0 0%	29 1%	0 0%	520 11%
SEP-2020	13 87%	1336 28%	2 13%	2440 51%	0 0%	497 10%	0 0%	29 1%	0 0%	504 11%
OCT-2020	10 59%	1444 30%	5 29%	2425 50%	0 0%	493 10%	0 0%	30 1%	2 12%	493 10%
NOV-2020	8 36%	1540 31%	9 41%	2476 50%	2 9%	480 10%	0 0%	27 1%	3 14%	489 10%
DEC-2020	10 53%	1625 33%	7 37%	2466 49%	2 11%	459 9%	0 0%	27 1%	0 0%	477 10%
JAN-2021	12 80%	1698 34%	3 20%	2462 49%	0 0%	442 9%	0 0%	27 1%	0 0%	469 9%
FEB-2021	14 64%	1774 35%	5 23%	2475 48%	3 14%	420 8%	0 0%	24 0%	0 0%	457 9%
MAR-2021	23 72%	1839 35%	9 28%	2491 48%	0 0%	418 8%	0 0%	24 0%	0 0%	454 9%
APR-2021	15 75%	1901 36%	4 20%	2506 48%	1 5%	412 8%	0 0%	22 0%	0 0%	438 8%
MAY-2021	15 65%	1981 37%	7 30%	2508 47%	0 0%	397 7%	0 0%	22 0%	1 4%	438 8%
JUN-2021	16 76%	2058 38%	4 19%	2496 47%	1 5%	386 7%	0 0%	23 0%	0 0%	437 8%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category

MON-YYYY	Boosted PI + 2 N(t)RTIs		NNRTI + 2 N(t)RTIs		INSTI + 2 N(t)RTIs		2 drugs from 2 classes		IV 3 drugs from IV 3 classes		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2020	1617	21.98	1210	16.44	3562	48.41	55	0.75	761	10.34	153	2.08
FEB-2020	1573	21.46	1154	15.75	3643	49.71	55	0.75	757	10.33	147	2.01
MAR-2020	1540	20.85	1134	15.35	3755	50.83	57	0.77	759	10.27	142	1.92
APR-2020	1522	20.55	1129	15.24	3807	51.39	57	0.77	750	10.12	143	1.93
MAY-2020	1512	20.44	1111	15.02	3830	51.78	56	0.76	748	10.11	140	1.89
JUN-2020	1458	19.79	1084	14.71	3881	52.67	55	0.75	752	10.21	138	1.87
JUL-2020	1420	19.36	1058	14.43	3935	53.66	57	0.78	729	9.94	134	1.83
AUG-2020	1375	18.96	1026	14.14	3943	54.36	66	0.91	714	9.84	130	1.79
SEP-2020	1336	18.47	980	13.55	3998	55.27	79	1.09	710	9.82	130	1.80
OCT-2020	1308	18.00	964	13.27	4059	55.86	101	1.39	701	9.65	133	1.83
NOV-2020	1287	17.53	946	12.89	4129	56.25	159	2.17	697	9.49	123	1.68
DEC-2020	1272	17.31	924	12.57	4155	56.54	177	2.41	703	9.57	118	1.61
JAN-2021	1273	17.24	912	12.35	4193	56.77	202	2.73	693	9.38	113	1.53
FEB-2021	1232	16.70	894	12.12	4225	57.28	223	3.02	689	9.34	113	1.53
MAR-2021	1209	16.27	890	11.98	4274	57.51	246	3.31	707	9.51	106	1.43
APR-2021	1167	15.73	868	11.70	4321	58.23	273	3.68	690	9.30	101	1.36
MAY-2021	1146	15.38	858	11.51	4348	58.35	296	3.97	704	9.45	100	1.34
JUN-2021	1124	15.09	835	11.21	4363	58.56	324	4.35	706	9.48	99	1.33

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2020	12	0	2	1	4	4	490
FEB-2020	19	5	1	5	3	5	320
MAR-2020	23	4	0	3	1	10	550
APR-2020	8	0	0	3	0	5	686
MAY-2020	15	1	0	3	4	7	400
JUN-2020	9	1	0	3	4	1	380
JUL-2020	12	3	0	0	2	4	500
AUG-2020	11	3	1	3	2	1	225
SEP-2020	9	3	2	1	0	0	71
OCT-2020	13	2	1	1	3	3	381
NOV-2020	12	0	1	0	2	6	710
DEC-2020	13	3	3	3	0	4	260
JAN-2021	10	1	4	0	1	2	170
FEB-2021	14	0	2	3	4	5	365
MAR-2021	24	4	5	3	5	5	280
APR-2021	9	2	1	1	1	4	370
MAY-2021	15	1	1	3	2	4	480
JUN-2021	15	4	1	3	2	4	289

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2020	12527	4023
FEB-2020	12557	4039
MAR-2020	12558	4030
APR-2020	12536	4006
MAY-2020	12526	3994
JUN-2020	12504	3972
JUL-2020	12481	3939
AUG-2020	12449	3915
SEP-2020	12412	3887
OCT-2020	12389	3874
NOV-2020	12403	3875
DEC-2020	12380	3836
JAN-2021	12389	3838
FEB-2021	12381	3832
MAR-2021	12379	3821
APR-2021	12368	3808
MAY-2021	12363	3796
JUN-2021	12367	3792

Definitions:


Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved
Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month






3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants N = 7451
Jun-2021

BY HEALTH SERVICES DELIVERY AREA




BY HEALTH AUTHORITY






3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Jun-2021

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Jun-2021

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Jun-2021

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VANCOUVER BY POSTAL CODE






3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Jun-2021

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Jun-2021

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	6	6	*
	35-49	10	11	*
	50+	28	40	*
	Total HSDA:	44	57	29
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	74	99	57	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	399	539	308	
THOMPSON/CARIBOO/ SHUSWAP	20-34	19	19	11
	35-49	67	73	45
	50+	113	185	91
	Total HSDA:	199	277	147
Total HA:		716	972	541

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		716	972	541

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	576	780	436
Female	140	192	105

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	541	56	620	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	22	12
	5 years or more	12	8
	<5 years	10	9
	Total HSDA:	44	29
KOOTENAY BOUNDARY	10 years or more	50	36
	5 years or more	14	11
	<5 years	10	10
	Total HSDA:	74	57
OKANAGAN	10 years or more	253	187
	5 years or more	87	73
	<5 years	59	48
	Total HSDA:	399	308
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	120	91
	5 years or more	43	33
	<5 years	36	23
	Total HSDA:	199	147
Total HA:		716	541

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	445	326
5 years or more	156	125
<5 years	115	90
Total HA:	716	541

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	51	68	15	27
KOOTENAY BOUNDARY	76	126	26	47
OKANAGAN	228	966	57	294
THOMPSON/CARIBOO/SHUSWAP	141	532	37	129
Total:	496	1692	135	497

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	106

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	6
	20-34	31	33	28
	35-49	98	104	66
	50+	241	331	182
	Total HSDA:		376	474
FRASER NORTH	20-34	118	118	75
	35-49	347	370	262
	50+	609	966	474
	Total HSDA:		1074	1454
FRASER SOUTH	0-19	5	5	5
	20-34	118	120	86
	35-49	315	350	254
	50+	581	869	480
	Total HSDA:		1019	1344
Total HA:		2469	3272	1918

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	11	11	11
	20-34	267	271	189
	35-49	760	824	582
	50+	1431	2166	1136
Total HA:		2469	3272	1918

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1863	2500	1466
Female	606	772	452

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1918	52	640	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	229	173
	5 years or more	83	60
	<5 years	64	49
	Total HSDA:	376	282
FRASER NORTH	10 years or more	634	457
	5 years or more	246	198
	<5 years	194	156
	Total HSDA:	1074	811
FRASER SOUTH	10 years or more	618	490
	5 years or more	213	171
	<5 years	188	164
	Total HSDA:	1019	825
Total HA:		2469	1918

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1481	1120
	5 years or more	542	429
	<5 years	446	369
Total HA:		2469	1918

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	141	509	29	59
FRASER NORTH	255	1598	48	216
FRASER SOUTH	223	1648	53	500
Total:	619	3755	130	775

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	185
FRASER NORTH	661
FRASER SOUTH	456
Total:	1302

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		347	502
RICHMOND	20-34	34	35	20
	35-49	44	46	36
	50+	113	162	92
	Total HSDA:	191	243	148
VANCOUVER	0-19	9	9	7
	20-34	433	449	280
	35-49	1323	1473	951
	50+	2933	5089	2138
	Total HSDA:	4698	7020	3376
Total HA:		5236	7765	3809

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	12	12	10
	20-34	491	508	318
	35-49	1451	1612	1052
	50+	3282	5633	2429
Total HA:		5236	7765	3809

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Unknown	2	2	0
Male	4627	6817	3364
Female	607	946	445

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3809	54	650	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	201	163
	5 years or more	79	67
	<5 years	67	55
	Total HSDA:	347	285
RICHMOND	10 years or more	112	84
	5 years or more	37	29
	<5 years	42	35
	Total HSDA:	191	148
VANCOUVER	10 years or more	3043	2107
	5 years or more	964	716
	<5 years	691	553
	Total HSDA:	4698	3376
Total HA:		5236	3809

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	3356	2354
5 years or more	1080	812
<5 years	800	643
Total HA:	5236	3809

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	180	407	55	83
RICHMOND	43	294	8	91
VANCOUVER	645	11142	216	5345
Total:	868	11843	279	5519

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	79

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		340	490
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		127	173
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		762	1088
Total HA:		1229	1751	945

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	6
	20-34	120	129	82
	35-49	282	329	222
	50+	821	1287	635
Total HA:		1229	1751	945

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1013	1443	776
Female	216	308	169

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	945	55	570	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	200	160
	5 years or more	73	56
	<5 years	67	55
	Total HSDA:	340	271
NORTH VANCOUVER ISLAND	10 years or more	81	65
	5 years or more	29	20
	<5 years	17	17
	Total HSDA:	127	102
SOUTH VANCOUVER ISLAND	10 years or more	447	307
	5 years or more	162	138
	<5 years	153	127
	Total HSDA:	762	572
Total HA:		1229	945

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	728	532
	5 years or more	264	214
	<5 years	237	199
Total HA:		1229	945

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	204	899	76	199
NORTH VANCOUVER ISLAND	152	273	48	76
SOUTH VANCOUVER ISLAND	217	1857	43	560
Total:	573	3029	167	835

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	56
NORTH VANCOUVER ISLAND	41
SOUTH VANCOUVER ISLAND	117
Total:	214

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	*	*	0
	35-49	*	*	11
	50+	*	*	10
	Total HSDA:	41	52	21
NORTH WEST	20-34	*	6	0
	35-49	*	40	18
	50+	*	69	32
	Total HSDA:	71	115	50
NORTHERN INTERIOR	0-19	6	6	*
	20-34	23	25	*
	35-49	61	76	*
	50+	103	175	*
	Total HSDA:	193	282	139
Total HA:		305	449	210

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	30	34	*
	35-49	103	136	*
	50+	166	273	*
Total HA:		305	449	210

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	190	280	131
Female	115	169	79

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	210	51	555	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	25	*
	5 years or more	10	*
	<5 years	6	*
	Total HSDA:	41	21
NORTH WEST	10 years or more	43	31
	5 years or more	17	11
	<5 years	11	8
	Total HSDA:	71	50
NORTHERN INTERIOR	10 years or more	88	66
	5 years or more	66	45
	<5 years	39	28
	Total HSDA:	193	139
Total HA:		305	210

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	156	109
	5 years or more	93	62
	<5 years	56	39
Total HA:		305	210

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries NORTHERN Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	40	62	4	5
NORTH WEST	80	166	15	33
NORTHERN INTERIOR	118	472	18	187
Total:	238	700	37	225

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	19
NORTHERN INTERIOR	13
Total:	38

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	5
	KOOTENAY BOUNDARY	6	9	6
	OKANAGAN	27	44	15
	THOMPSON/CARIBOO/SHUSWAP	23	47	16
	Total HA:	62	110	42
FRASER	FRASER EAST	37	49	27
	FRASER NORTH	52	89	41
	FRASER SOUTH	82	115	61
	Total HA:	171	253	129
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	27	50	24
	RICHMOND	8	13	6
	VANCOUVER	484	895	382
	Total HA:	519	958	412
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	49	82	40
	NORTH VANCOUVER ISLAND	16	26	12
	SOUTH VANCOUVER ISLAND	40	84	30
	Total HA:	105	192	82
NORTHERN	NORTH EAST	10	14	6
	NORTH WEST	30	63	22
	NORTHERN INTERIOR	70	111	60
	Total HA:	110	188	88
Total:		967	1701	753

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	609	1092	472
Female	358	609	281

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	753	52	510	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.





Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intelence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





Monthly Report

Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

N(t)RTI: a category of drug encompassing both NUCLEOSIDE ANALOG and NUCLEOTIDE ANALOG

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





Monthly Report

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

